Form 8-K - Current report:
SEC Accession No. 0001193125-24-284219
Filing Date
2024-12-23
Accepted
2024-12-23 16:32:57
Documents
14
Period of Report
2024-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d922033d8k.htm   iXBRL 8-K 25754
2 EX-10.1 d922033dex101.htm EX-10.1 946786
  Complete submission text file 0001193125-24-284219.txt   1322578

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lnth-20241219.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lnth-20241219_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lnth-20241219_pre.xml EX-101.PRE 11264
16 EXTRACTED XBRL INSTANCE DOCUMENT d922033d8k_htm.xml XML 3641
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36569 | Film No.: 241574131
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)